Labcorp Holdings Inc. (ETR:N6B)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.39B +20.2% |
| Revenue (ttm) | 12.56B +6.4% |
| Net Income | 877.31M +31.3% |
| EPS | 10.57 +33.2% |
| Shares Out | n/a |
| PE Ratio | 25.52 |
| Forward PE | 16.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 274.00 |
| Previous Close | 272.00 |
| Day's Range | 274.00 - 274.00 |
| 52-Week Range | 224.00 - 274.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseas... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer
Labcorp (LH) announced the nationwide availability of Roche’s (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PT...
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global l...
Labcorp price target raised to $309 from $300 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Labcorp (LH) to $309 from $300 following quarterly results. The firm keeps a Neutral rating on the shares. Published…
Labcorp price target raised to $360 from $330 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Labcorp (LH) to $360 from $330 and keeps an Overweight rating on the shares.
Labcorp price target raised to $338 from $308 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Labcorp (LH) to $338 from $308 and keeps an Overweight rating on the shares. Labcorp’s Q2 organic growth volume seemed a bit…
Labcorp price target raised to $306 from $276 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Labcorp (LH) to $306 from $276 and keeps a Hold rating on the shares.
Labcorp price target raised to $360 from $320 at BofA
BofA raised the firm’s price target on Labcorp (LH) to $360 from $320 and keeps a Buy rating on the shares after having updated the firm’s model for yesterday’s Q2…
Labcorp price target raised to $352 from $338 at Baird
Baird raised the firm’s price target on Labcorp (LH) to $352 from $338 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results. Published…
Labcorp price target raised to $320 from $290 at Barclays
Barclays raised the firm’s price target on Labcorp (LH) to $320 from $290 and keeps an Equal Weight rating on the shares.
Labcorp Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 6% revenue growth, margin expansion, and double-digit adjusted EPS growth, driven by strong Diagnostics and BLS performance, specialty testing, and consumer initiatives. Full-year guidance for revenue and EPS was raised, with continued margin expansion expected.
Labcorp Holdings Earnings release: Q2 2026
Labcorp Holdings released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Labcorp Holdings Slides: Q2 2026
Labcorp Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Labcorp Holdings Quarterly report: Q2 2026
Labcorp Holdings has published its Q2 2026 quarterly earnings report on July 30, 2026.
Labcorp raises annual profit forecast on strong testing demand
Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, as steady demand for diagnostic testing and growth in its drug-devel...
Labcorp raises FY26 adjusted EPS view to $18.10-$18.55 from $17.70-$18.35
Consensus $18.01. Raises FY26 revenue view to $14.71B-$14.83B from $14.65B-$14.8B, consensus $14.71B. The company said, “Labcorp (LH) is updating 2026 full year guidance to reflect its second quarter ...
Labcorp reports Q2 adjusted EPS $4.99, consensus $4.77
Reports Q2 revenue $3.73B, consensus $3.71B. “Labcorp (LH) delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting ...
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs.
Labcorp launches Marker by Labcorp Genetic Health Panel
Labcorp (LH) announced the launch of Marker by Labcorp Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actiona...
Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers ...
Labcorp awarded $364.7M Defense Health Agency contract
Labcorp (LH) was awarded $364.7M for a single-award, indefinite delivery/indefinite quantity contract utilizing firm-fixed-price task orders to provide the Defense Health Agency with commercial clinic...
HCA preannouncement negative for Quest, Labcorp, says Barclays
Barclays views HCA Healthcare’s (HCA) preannouncement on Affordable Care Act coverage lost during Q2 is a negative read-through for Quest Diagnostics (DGX) and Labcorp (LH). HCA’s Affordable Care Act ...
Labcorp price target raised to $320 from $300 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Labcorp (LH) to $320 from $300 and keeps a Buy rating on the shares as part of the firm’s Q2…
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has de...
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second...
Labcorp announces nationwide availability of ColoSense
Labcorp (LH) announced the nationwide availability of ColoSense, the only RNA-based at-home test for colorectal cancer screening approved by the U.S. FDA. Offered through a commercial collaboration wi...